A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Ribociclib (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Nov 2017 Planned End Date changed from 15 Dec 2018 to 29 Apr 2019.
- 10 Jun 2017 Biomarkers information updated
- 01 May 2017 Planned number of patients changed from 106 to 124.